

ForPatients

by Roche

Breast Cancer HER2-Positive Breast Cancer

A Study to Evaluate the Safety and Effectiveness of Trastuzumab Emtansine (T-DM1) as Therapy in Chinese Participants With HER2 Positive Advanced Breast Cancer

Trial Status

Active, not recruiting

Trial Runs In

1 Countries

Trial Identifier

NCT05945927 ML44675

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

Trial Summary:

This study is a post-marketing, observational, multicenter, prospective study. It will investigate the the safety and effectiveness of T-DM1 in the Chinese population in real-world clinical practice.

Hoffmann-La Roche

Sponsor

N/A

Phase

NCT05945927 ML44675

Trial Identifiers

Eligibility Criteria:

Gender

Female

Age

>=18 Years

Healthy Volunteers

No
